Table 2.
Pharmacokinetic parameters after a single subcutaneous administration of ozoralizumab
| Dose (mg) | N | Cmax (μg/mL) | tmax (h) | AUC0-last (h·μg/mL) | AUC0-∞ (h·μg/mL) | t1/2 (day) | CL/F (mL/h) | Vd/F (L) |
|---|---|---|---|---|---|---|---|---|
| 30 | 77 | 4.55 ± 1.18 | 144 (23.2–336) | 2050 ± 523 | 3280 ± 1280a | 18.2 ± 8.21a | 10.4 ± 3.91a | 5.88 ± 1.72a |
| 80 | 80 | 12.5 ± 2.84 | 144 (22.1–212) | 5540 ± 1080 | 8860 ± 3010 | 17.9 ± 5.98 | 9.92 ± 2.93 | 5.71 ± 1.09 |
Data are expressed as mean ± standard deviation or median (range)
AUC area under the plasma concentration–time curve, AUC0-∞ AUC from 0 to infinity, AUC0-last AUC from 0 to the last quantifiable data point, CL/F apparent clearance, Cmax maximum concentration, t1/2 elimination half-life, tmax time to maximum concentration, Vd/F apparent volume of distribution
aN = 74